Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
received:
17
06
2024
accepted:
23
07
2024
revised:
19
07
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
20
8
2024
Statut:
aheadofprint
Résumé
We assessed outcomes of allogeneic transplantation (HSCT) in favorable risk AML in CR1 over 3 time periods. 1850 patients were included, 2005 to 2009- 222, 2010 to 2014 -392, and 2015 to 2021-1236; 526 with t (8:21), 625 with inv (16), and 699 with NPM1
Identifiants
pubmed: 39164484
doi: 10.1038/s41409-024-02379-z
pii: 10.1038/s41409-024-02379-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.
pubmed: 35797463
doi: 10.1182/blood.2022016867
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.
pubmed: 35767897
pmcid: 9479031
doi: 10.1182/blood.2022015850
Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnostic, risk-stratification, and management. Am J Hematol. 2023;98:502–26.
pubmed: 36594187
doi: 10.1002/ajh.26822
Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, et al. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy. Transpl Cell Ther. 2021;27:6–20.
doi: 10.1016/j.bbmt.2020.09.020
Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, et al. Development and validation of a disease risk stratification system for patients with hematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021;8:e205–15.
pubmed: 33636142
pmcid: 9190021
doi: 10.1016/S2352-3026(20)30394-X
Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, et al. Prediction of allogeneic hematopoietic stem-cell transplantation mortality 100 days after transplantation using a machine learning algorithm: a European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. J Clin Oncol. 2015;33:3144–51.
pubmed: 26240227
doi: 10.1200/JCO.2014.59.1339
Borthakur G, Kantarijian H. Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J 2021;11:114.
pubmed: 34135311
pmcid: 8209225
doi: 10.1038/s41408-021-00503-6
Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, et al. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv. 2017;1:1546–50.
pubmed: 29296796
pmcid: 5728474
doi: 10.1182/bloodadvances.2017009019
Schlenk RF, Benner A, Krauter J. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22:3741–50.
pubmed: 15289486
doi: 10.1200/JCO.2004.03.012
Appelbaum FR, Kopecky KJ, Tallman MS. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haeamtol. 2006;135:165–73.
doi: 10.1111/j.1365-2141.2006.06276.x
Mosna F, Papayannidis C, Martinelli G. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. Am J Hematol. 2015;90:515–23.
pubmed: 25753065
doi: 10.1002/ajh.24000
Falini B, Brunetti L, Martelli MP. How I diagnosed and treat NPM1-mutated AML. Blood. 2021;137:589–99.
pubmed: 33171486
doi: 10.1182/blood.2020008211
Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9:579–90.
pubmed: 22949046
doi: 10.1038/nrclinonc.2012.150
Halaburda K, Labopin M, Mailhol A, Socié G, Craddock C, Aljurf M, et al. Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020;105:1723–30.
pubmed: 31439677
pmcid: 7271580
doi: 10.3324/haematol.2019.222810
Loke J, Buka R, Craddock C. Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how. Front Immunol. 2021;12:659595.
pubmed: 34012445
pmcid: 8126705
doi: 10.3389/fimmu.2021.659595
Bazarbachi A, Schmid C, Labopin M, Beelen D, Blau IW, Potter V, et al. Evaluation of Trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years. Clin Cancer Res. 2020;26:6475–82.
pubmed: 32988970
doi: 10.1158/1078-0432.CCR-20-3134
Nagler A, Ngoya M, Galimard JE, Labopin M, Bornhäuser M, Stelljes M, et al. Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: An ALWP/EBMT Analysis. Clin Cancer Res. 2022;28:4258–66.
pubmed: 35670780
doi: 10.1158/1078-0432.CCR-22-0809
Bazarbachi A, Labopin M, Gedde-Dahl T, Remenyi P, Forcade E, Kröger N, et al. Improved posttransplant outcomes in recent years for AML Patients with FLT3-ITD and wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party. Clin Cancer Res. 2023;29:4441–8.
pubmed: 37603683
doi: 10.1158/1078-0432.CCR-23-0954
Bazarbachi A, Labopin M, Moukalled N, Kröger N, Rautenberg C, Schetelig J et al. Improvements in posttransplant outcomes over two decades in older patients with acute myeloid leukemia in the EBMT ALWP Study. Clin Cancer Res. 2024:OF1-OF10.
Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6:e573–584.
pubmed: 31477550
doi: 10.1016/S2352-3026(19)30158-9
Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020;4:6283–90.
pubmed: 33351121
pmcid: 7756984
doi: 10.1182/bloodadvances.2020003418
Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji RM, et al. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. J Intern Med. 2019;285:407–41.
pubmed: 30372796
doi: 10.1111/joim.12854
McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohort. Ann Intern Med. 2020;172:229–39.
pubmed: 31958813
pmcid: 7847247
doi: 10.7326/M19-2936
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.
doi: 10.1016/j.bbmt.2009.07.004
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.
pubmed: 6996481
doi: 10.1016/0002-9343(80)90380-0
Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610–1.
doi: 10.1038/bmt.2015.305
Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2:2–4.
pubmed: 34595436
pmcid: 8432337
doi: 10.2991/chi.d.191207.001
Andersen PK, Klein JP, Zhang MJ. Testing for center effects in multi-center survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489–500.
pubmed: 10398287
doi: 10.1002/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2020. https://www.R-project.org/ .
A language and environment for statistical computing. https://www.R-project.org/ . R Core Team: R Foundation for Statistical Computing, Vienna, Austria; 2020.
Rashidi A, Ebadi M, Colditz GA, DiPersio JF. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol Blood Marrow Transpl. 2016;22:651–7.
doi: 10.1016/j.bbmt.2015.10.019
Maffini E, Labopin M, Kröger N, Finke J, Stelljes M, Schroeder T,et al. Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. https://doi.org/10.1038/s41409-024-02275-6 2024.
Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Cámara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transpl. 2021;56:1651–64.
doi: 10.1038/s41409-021-01227-8
Bittencourt MC, Ciurea SO. Recent advances in allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transpl. 2020;26:e215–221.
doi: 10.1016/j.bbmt.2020.06.007
Schlenk RF, et al. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transpl. 2008;14:187–96.
doi: 10.1016/j.bbmt.2007.10.006
Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for hematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11:e147–159.
pubmed: 38184001
doi: 10.1016/S2352-3026(23)00342-3
Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Anti -lymphocyte globulin for prevention of chronic graft-versus-host disease. N. Engl J Med. 2016;374:43–53.
pubmed: 26735993
doi: 10.1056/NEJMoa1506002
Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338–48.
pubmed: 37342922
pmcid: 10575613
doi: 10.1056/NEJMoa2215943
Gorin NC, Labopin M, Frassoni F, Milpied N, Attal M, Blaise D, et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:3183–8.
pubmed: 18506024
doi: 10.1200/JCO.2007.15.3106
Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, et al. Prognosis of inv (16)/t (16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102:462–9.
pubmed: 12649129
doi: 10.1182/blood-2002-11-3527
Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, et al. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. Leukemia. 2019;33:686–95.
pubmed: 30573777
doi: 10.1038/s41375-018-0302-y
Moukalled N, Labopin M, Versluis J, Socié G, Blaise D, Salmenniemi U, et al. Complex karyotype but no other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Am J Hematol. 2024;99:360–9.
pubmed: 38165072
doi: 10.1002/ajh.27187
Aldoss I, Nakamura R, Yang D, Salhotra A, Stein AS, Pullarkat V, et al. Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia. Bone Marrow Transpl. 2020;55:473–5.
doi: 10.1038/s41409-019-0553-x
Shimoni A, Labopin M, Angelucci E, Blaise D, Ciceri F, Koc Y, et al. The association of graft-versus-leukemia effect and graft-versus-host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. Bone Marrow Transpl. 2022;57:384–90.
doi: 10.1038/s41409-021-01493-6
Leotta S, Condorelli A, Sciortino R, Milone GA, Bellofiore C, Garibaldi B et al. Prevention and treatment of acute myeloid leukemia relapse after hematopoietic stem cell transplantation: the state of the art and future perspectives. J Clin Med. 2022 4;11253.
Lee CJ, Savani BN, Mohty M, Gorin NC, Labopin M, Ruggeri A, et al. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2019;54:519–30.
doi: 10.1038/s41409-018-0286-2
Boddu P, Kantarjian H. Core binding factor acute myeloid leukemia-2021 treatment algorithm. Blood CA J. 2021;11:14.
Darwish C, Farina K, Tremblay D. The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment. Blood Rev. 2023;62:101117.
pubmed: 37524647
doi: 10.1016/j.blre.2023.101117
Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016;48:1551–6.
pubmed: 27798625
pmcid: 5508996
doi: 10.1038/ng.3709
Nagler A, Labopin M, Mielke S, Passweg J, Blaise D, Gedde-Dahl T, et al. Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. Bone Marrow Transpl. 2023;58:791–800.
doi: 10.1038/s41409-023-01980-y
Gorin NC, Labopin M, Blaise D, de Groot M, Socié G, Bourhis JH, et al. Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: a retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Cancer. 2020;126:1004–15.
pubmed: 31774557
doi: 10.1002/cncr.32629
Nagler A, Labopin M, Dholaria B, Angelucci E, Afanasyev B, Cornelissen JJ, et al. Comparison of haploidentical bone marrow versus matched unrelated donor peripheral blood stem cell transplantation with posttransplant cyclophosphamide in patients with acute leukemia. Clin Cancer Res. 2021;27:843–51.
pubmed: 33148668
doi: 10.1158/1078-0432.CCR-20-2809
Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji RM, Griskevicius L et al. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. https://doi.org/10.1038/s41409-024-02284-5 2024.
Greinix HT, Eikema DJ, Koster L, Penack O, Yakoub-Agha I, Montoto S, et al. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. Haematologica. 2022;107:1054–63.
pubmed: 34162176
doi: 10.3324/haematol.2020.265769
Ishikawa Y. Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia. Rinsho Ketsuek 2018;59:1997–2006.
Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, et al. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. Ann Hematol. 2019;98:83–91.
pubmed: 30251205
doi: 10.1007/s00277-018-3492-5
Bourne G, Diebold K, Espinoza-Gutarra M, Al-Kadhimi Z, Bachiashvili K, Rangaraju S, et al. Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia. Leuk Res 2024;139:107467.
pubmed: 38460432
doi: 10.1016/j.leukres.2024.107467
Ragon BK, Daver N, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, et al. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2017;92:845–50.
pubmed: 28494506
pmcid: 5779853
doi: 10.1002/ajh.24782
Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, et al. Activity of decitabine as maintenance therapy in core binding factorable acute myeloid leukemia. Am J Hematol. 2022;97:574–82.
pubmed: 35150150
pmcid: 9303262
doi: 10.1002/ajh.26496
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29.
pubmed: 32786187
doi: 10.1056/NEJMoa2012971
Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, et al. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. Leukemia 2018;32:1621–30.
pubmed: 29720733
doi: 10.1038/s41375-018-0129-6
Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571–83.
pubmed: 37116523
doi: 10.1016/S0140-6736(23)00464-6
Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, et al. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023;98:1711–20.
pubmed: 37635400
doi: 10.1002/ajh.27054
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, et al. Gilteritinib as post-transplant maintenance for acute myeloid leukemia with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42:1766–75.
pubmed: 38471061
doi: 10.1200/JCO.23.02474